ahlam1399
08-30-2016, 11:55 AM
Vectura?s asthma therapy misses primary endpoint in final stage trial
(Reuters) - Respiratory drug specialist Vectura Group Plc said its asthma therapy Flutiform had **t met the primary endpoint in a phase III trial carried out by its European partner Mundipharma.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=VP2kjaNpiL8:ndc4r_4PECw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=VP2kjaNpiL8:ndc4r_4PECw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=VP2kjaNpiL8:ndc4r_4PECw:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=VP2kjaNpiL8:ndc4r_4PECw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=VP2kjaNpiL8:ndc4r_4PECw:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/VP2kjaNpiL8
(Reuters) - Respiratory drug specialist Vectura Group Plc said its asthma therapy Flutiform had **t met the primary endpoint in a phase III trial carried out by its European partner Mundipharma.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=VP2kjaNpiL8:ndc4r_4PECw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=VP2kjaNpiL8:ndc4r_4PECw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=VP2kjaNpiL8:ndc4r_4PECw:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=VP2kjaNpiL8:ndc4r_4PECw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=VP2kjaNpiL8:ndc4r_4PECw:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/VP2kjaNpiL8